Latest News

  • Alkermes to Present Data on Two-Month Dosing Option Of ARISTADA® at 16th International Congress on Schizophrenia Research Read More
  • Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of Multiple Sclerosis Read More
  • Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference Read More

Investors

Learn more Learn More Alkermes PLC Investor Relations

Working at Alkermes

Join Our Team Join Our Team Working at Alkermes